Revance Releases Fourth Quarter and Full Year 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Revance Theraputics (RVNC) Pipeline is Underappreciated - Guggenheim
March 3, 2016 9:05 AM ESTGuggenheim analyst, Louise Chen, believes Revance Therapeutics' (NASDAQ: RVNC) pipeline prospects are underappreciated. She expects five launches over five years beginning in '19 that should drive upward earnings revisions and multiple expansion to levels not reflected in consensus expectations. No change to Buy rating or $55 PT.
The launches include:
1) RT001, topical for Crows Feet Lines in '19
2) RT002, injectable for glabellar... More
Revance Therapeutics (RVNC) Tops Q4 EPS by 3c
March 2, 2016 4:29 PM ESTRevance Therapeutics (NASDAQ: RVNC) reported Q4 EPS of ($0.83), $0.03 better than the analyst estimate of ($0.86). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $60 thousand.
For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.
... More